SciPod podcast

Breaking Barriers in Cancer Care: How Lenvatinib Offers Hope for Resistant Thyroid Cancer

06/06/2025
0:00
26:16
Recuar 15 segundos
Avançar 15 segundos
Thyroid cancer is one of the more common cancers globally, and for most patients, the prognosis is generally favorable with timely and effective treatment. The usual course involves surgery to remove the thyroid gland, followed by radioactive iodine therapy to eliminate any remaining cancerous cells. However, for a subset of patients, the story is far more complicated. When thyroid cancer no longer responds to radioiodine therapy, a condition known as radioiodine-refractory differentiated thyroid cancer, the outlook becomes significantly more daunting. These patients face limited treatment options and a much grimmer prognosis.

Mais episódios de "SciPod"